Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Jazz Pharmaceuticals plcJAZZ · Entity 818 | Director | August 31, 2026 | September 02, 2026 |
| OncoMed Pharmaceuticals IncOMED · Entity 158190 | Director | June 22, 2018 | June 25, 2018 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Jazz Pharmaceuticals plc
Report date August 31, 2026 · Filed September 02, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 9,466 |
Ending reported balance
After 2026-08-31 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-08-31 · Tax withholding · Disposed 1,692 · Balance 9,480 F1: Shares sold to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. Row 2 · 2026-08-31 · Tax withholding · Disposed 14 · Balance 9,466 F1: Shares sold to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares sold to satisfy tax obligations arising out of the vesting of previously granted restricted stock units.
OncoMed Pharmaceuticals Inc
Report date June 22, 2018 · Filed June 25, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.55 · Expires 2028-06-22 | Direct | 15,000 |
Reported balance
After 2018-06-22 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2018-06-22 · Grant · Acquired 15,000 · Balance 15,000 F1: The option vests as to 100% of the shares subject thereto upon the earlier of one year following the grant date or the date of the subsequent year's annual meeting of stockholders, subject to the Reporting Person's continued service to the Issuer through such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests as to 100% of the shares subject thereto upon the earlier of one year following the grant date or the date of the subsequent year's annual meeting of stockholders, subject to the Reporting Person's continued service to the Issuer through such vesting date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Theravance Biopharma, Inc.
Report date September 23, 2026 · Filed September 25, 2026
Section 16 reporting ended · disclosed 2026-09-25. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2026-09-23 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2026-09-23 · Disposition to issuer · Disposed 1,382,272 · Balance 228,750 F1: On September 23, 2026, pursuant to that certain Agreement and Plan of Merger (the "Merger Agreement"), dated June 28, 2026, by and among the Issuer, Zymeworks Inc. ("Parent"), and Zymeworks Merger Sub 1, a wholly owned subsidiary of Parent, the Issuer became a wholly owned subsidiary of Parent (the "Merger"). At the effective time of the Merger (the "Effective Time"), pursuant to the Merger Agreement, each ordinary share, par value $0.00001 per share, of the Issuer ("Ordinary Share") held by the reporting person as of immediately prior to the Effective Time was cancelled and converted into the right to receive (i) $17.00 in cash, without interest (the "Per Share Cash Consideration") and (ii) one contingent value right (a "CVR"). Each CVR represents a non-tradeable contractual contingent right to receive cash payments based on the achievement of certain commercial milestones following the Effective Time. Row 2 · 2026-09-23 · Disposition to issuer · Disposed 151,875 · Balance 76,875 F2: At the Effective Time, pursuant to the Merger Agreement, each award of restricted stock units of the Issuer (a "Company RSU Award") that was outstanding as of immediately prior to the Effective Time was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the Per Share Cash Consideration multiplied by (ii) the number of Ordinary Shares underlying such Company RSU Award (subject to any required tax withholdings as provided in the Merger Agreement) plus (iii) one CVR for each Ordinary Share underlying such Company RSU Award. Row 3 · 2026-09-23 · Disposition to issuer · Disposed 76,875 · Balance 0 F3: As of immediately prior to the Effective Time, each award of performance restricted stock units of the Issuer (a "Company PSU Award") that was outstanding as of immediately prior to the Effective Time was cancelled in exchange for the right to receive an amount in cash, without interest, equal to (i) the Per Share Cash Consideration multiplied by (ii) the number of Ordinary Shares with respect to such Company PSU Award that remained outstanding and unreleased as of immediately prior to the Effective Time, plus (iii) one CVR for each Ordinary Share underlying such Company PSU Award. |
| Ordinary SharesSEC Table I · non-derivative | IndirectAs Custodian | 0 |
Reported balance
After 2026-09-23 transaction · row 4
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 4 · 2026-09-23 · Disposition to issuer · Disposed 23,400 · Balance 0 F1: On September 23, 2026, pursuant to that certain Agreement and Plan of Merger (the "Merger Agreement"), dated June 28, 2026, by and among the Issuer, Zymeworks Inc. ("Parent"), and Zymeworks Merger Sub 1, a wholly owned subsidiary of Parent, the Issuer became a wholly owned subsidiary of Parent (the "Merger"). At the effective time of the Merger (the "Effective Time"), pursuant to the Merger Agreement, each ordinary share, par value $0.00001 per share, of the Issuer ("Ordinary Share") held by the reporting person as of immediately prior to the Effective Time was cancelled and converted into the right to receive (i) $17.00 in cash, without interest (the "Per Share Cash Consideration") and (ii) one contingent value right (a "CVR"). Each CVR represents a non-tradeable contractual contingent right to receive cash payments based on the achievement of certain commercial milestones following the Effective Time. |
| Ordinary SharesSEC Table I · non-derivative | IndirectBy Trust | 0 |
Reported balance
After 2026-09-23 transaction · row 5
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 5 · 2026-09-23 · Disposition to issuer · Disposed 92,567 · Balance 0 F1: On September 23, 2026, pursuant to that certain Agreement and Plan of Merger (the "Merger Agreement"), dated June 28, 2026, by and among the Issuer, Zymeworks Inc. ("Parent"), and Zymeworks Merger Sub 1, a wholly owned subsidiary of Parent, the Issuer became a wholly owned subsidiary of Parent (the "Merger"). At the effective time of the Merger (the "Effective Time"), pursuant to the Merger Agreement, each ordinary share, par value $0.00001 per share, of the Issuer ("Ordinary Share") held by the reporting person as of immediately prior to the Effective Time was cancelled and converted into the right to receive (i) $17.00 in cash, without interest (the "Per Share Cash Consideration") and (ii) one contingent value right (a "CVR"). Each CVR represents a non-tradeable contractual contingent right to receive cash payments based on the achievement of certain commercial milestones following the Effective Time. |
| Share Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.24 · Expires 2032-02-24 | Direct | 0 |
Reported balance
After 2026-09-23 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-09-23 · Disposition to issuer · Disposed 515,000 · Balance 0 F4: At the Effective Time, each option to purchase Ordinary Shares outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested (a "Company Option"), was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the excess, if any, of the Per Share Cash Consideration over the exercise price of such Company Option, multiplied by (ii) the number of Ordinary Shares underlying such Company Option plus (iii) one CVR for each Ordinary Share underlying such Company Option. |
Filing footnotes · ownership attribution and instrument terms
F1: On September 23, 2026, pursuant to that certain Agreement and Plan of Merger (the "Merger Agreement"), dated June 28, 2026, by and among the Issuer, Zymeworks Inc. ("Parent"), and Zymeworks Merger Sub 1, a wholly owned subsidiary of Parent, the Issuer became a wholly owned subsidiary of Parent (the "Merger"). At the effective time of the Merger (the "Effective Time"), pursuant to the Merger Agreement, each ordinary share, par value $0.00001 per share, of the Issuer ("Ordinary Share") held by the reporting person as of immediately prior to the Effective Time was cancelled and converted into the right to receive (i) $17.00 in cash, without interest (the "Per Share Cash Consideration") and (ii) one contingent value right (a "CVR"). Each CVR represents a non-tradeable contractual contingent right to receive cash payments based on the achievement of certain commercial milestones following the Effective Time.
F2: At the Effective Time, pursuant to the Merger Agreement, each award of restricted stock units of the Issuer (a "Company RSU Award") that was outstanding as of immediately prior to the Effective Time was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the Per Share Cash Consideration multiplied by (ii) the number of Ordinary Shares underlying such Company RSU Award (subject to any required tax withholdings as provided in the Merger Agreement) plus (iii) one CVR for each Ordinary Share underlying such Company RSU Award.
F3: As of immediately prior to the Effective Time, each award of performance restricted stock units of the Issuer (a "Company PSU Award") that was outstanding as of immediately prior to the Effective Time was cancelled in exchange for the right to receive an amount in cash, without interest, equal to (i) the Per Share Cash Consideration multiplied by (ii) the number of Ordinary Shares with respect to such Company PSU Award that remained outstanding and unreleased as of immediately prior to the Effective Time, plus (iii) one CVR for each Ordinary Share underlying such Company PSU Award.
F4: At the Effective Time, each option to purchase Ordinary Shares outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested (a "Company Option"), was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the excess, if any, of the Per Share Cash Consideration over the exercise price of such Company Option, multiplied by (ii) the number of Ordinary Shares underlying such Company Option plus (iii) one CVR for each Ordinary Share underlying such Company Option.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 14, 2022 Filed Dec 17, 2022 00:36 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | SaleOrdinary Shares | 50,000 | $11.19 | $559,500.00 |
DisclosureSEC source: 0001415889-22-012648 · form4-12172022_121226.xml · nonDerivative · entry 2 Winningham Rick E · CIK 0001302443 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,350,797 F2 · price: This transaction was executed in multiple trades at prices from $11.17 to $11.235 The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or any security holder of the issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| December 13, 2022 Filed Dec 17, 2022 00:36 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | GiftOrdinary Shares | 9,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-22-012648 · form4-12172022_121226.xml · nonDerivative · entry 1 Winningham Rick E · CIK 0001302443 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,400,797 F1 · price: Bona Fide Gift. No compensation was given to the donor for the gifting of shares. Read SEC document |
| November 20, 2022 Filed Nov 22, 2022 21:09 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | Tax withholdingOrdinary Shares | 15,804 | $10.85 | $171,473.40 |
DisclosureSEC source: 0001415889-22-011673 · form4-11222022_091120.xml · nonDerivative · entry 1 Winningham Rick E · CIK 0001302443 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,409,797 F1 · shares: Shares withheld to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. The share withholding transaction was with the issuer and did not involve an open market transaction. F2 · balance_after: Includes 817 shares acquired under the Theravance Biopharma, Inc. 2013 Employee Share Purchase Plan on November 15, 2022. Read SEC document |
| August 19, 2022 Filed Aug 23, 2022 23:03 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | Tax withholdingOrdinary Shares | 15,804 | $9.34 | $147,609.36 |
DisclosureSEC source: 0001415889-22-008985 · form4-08232022_040838.xml · nonDerivative · entry 1 Winningham Rick E · CIK 0001302443 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,424,784 F1 · shares: Shares withheld to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. The share withholding transaction was with the issuer and did not involve an open market transaction. Read SEC document |
| August 08, 2022 Filed Aug 9, 2022 22:52 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | SaleOrdinary Shares | 1,089 | $152.32 | $165,879.31 |
DisclosureSEC source: 0001765581-22-000102 · edgardoc.xml · nonDerivative · entry 2 Winningham Rick E · CIK 0001302443 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,610 F2 · kind: Shares sold to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. Read SEC document |
| August 05, 2022 Filed Aug 9, 2022 22:52 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | GrantOrdinary Shares | 2,561 | $0.00 | $0.00 |
DisclosureSEC source: 0001765581-22-000102 · edgardoc.xml · nonDerivative · entry 1 Winningham Rick E · CIK 0001302443 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,699 F1 · kind: These restricted stock units are granted pursuant to the Issuer's 2007 Amended and Restated Non-Employee Directors Stock Award Plan. Each restricted stock unit represents a contingent right to receive one ordinary share upon the vesting of the unit. Subject to the Reporting Person's continuous service and certain additional conditions, these units will vest in full on July 28, 2023. Read SEC document |
| May 20, 2022 Filed May 24, 2022 23:19 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | Tax withholdingOrdinary Shares | 11,025 | $8.74 | $96,358.50 |
DisclosureSEC source: 0001415889-22-005633 · form4-05242022_040502.xml · nonDerivative · entry 1 Winningham Rick E · CIK 0001302443 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,440,588 F1 · shares: Shares withheld to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. The share withholding transaction was with the issuer and did not involve an open market transaction. F2 · balance_after: Includes 2,313 shares acquired under the Theravance Biopharma, Inc. 2013 Employee Share Purchase Plan on May 13, 2022. Read SEC document |
| February 25, 2022 Filed Mar 2, 2022 00:18 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | GrantShare Option (Right to Buy) · Derivative | 515,000 | $0.00 Strike: $10.24 | $0.00 |
DisclosureSEC source: 0001415889-22-002078 · form4-03012022_040310.xml · derivative · entry 3 Winningham Rick E · CIK 0001302443 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 515,000 Underlying: Ordinary Shares · 515,000 shares Expires 2032-02-24 F1 · derivative.exercise_date: 25% of this option may be exercised when the optionee completes 12 months of continuous Service after the Date of Grant. Any remaining unvested shares may be exercised with respect to an additional 1/48th of the shares subject to the option when the optionee completes each month of continuous Service thereafter. Read SEC document |
| February 25, 2022 Filed Mar 2, 2022 00:18 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | GrantOrdinary Shares | 170,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-22-002078 · form4-03012022_040310.xml · nonDerivative · entry 1 Winningham Rick E · CIK 0001302443 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,449,300 Read SEC document |
| February 18, 2022 Filed Feb 23, 2022 23:38 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | Tax withholdingOrdinary Shares | 22,710 | $9.61 | $218,243.10 |
DisclosureSEC source: 0001415889-22-001703 · form4-02232022_030205.xml · nonDerivative · entry 1 Winningham Rick E · CIK 0001302443 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,279,300 F1 · shares: Shares withheld to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. The share withholding transaction was with the issuer and did not involve an open market transaction. Read SEC document |
| November 19, 2021 Filed Nov 24, 2021 01:20 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | Tax withholdingOrdinary Shares | 11,404 | $8.36 | $95,337.44 |
DisclosureSEC source: 0001415889-21-005463 · form4-11232021_051101.xml · nonDerivative · entry 1 Winningham Rick E · CIK 0001302443 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,302,010 F1 · shares: Shares withheld to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. The share withholding transaction was with the issuer and did not involve an open market transaction. Read SEC document |
| August 20, 2021 Filed Aug 24, 2021 23:05 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | Tax withholdingOrdinary Shares | 11,404 | $14.05 | $160,226.20 |
DisclosureSEC source: 0001179110-21-008404 · edgar.xml · nonDerivative · entry 1 Winningham Rick E · CIK 0001302443 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,313,414 F1 · shares: Shares withheld to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. The share withholding transaction was with the issuer and did not involve an open market transaction. Read SEC document |
| August 06, 2021 Filed Aug 10, 2021 21:42 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | SaleOrdinary Shares | 1,306 | $147.96 | $193,235.76 |
DisclosureSEC source: 0001765581-21-000112 · edgardoc.xml · nonDerivative · entry 1 Winningham Rick E · CIK 0001302443 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,138 F1 · kind: Shares sold to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. Read SEC document |
| July 29, 2021 Filed Aug 2, 2021 22:29 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | GrantOrdinary Shares | 2,246 | $0.00 | $0.00 |
DisclosureSEC source: 0001765581-21-000087 · edgardoc.xml · nonDerivative · entry 1 Winningham Rick E · CIK 0001302443 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,444 F1 · kind: These restricted stock units are granted pursuant to the Issuer's 2007 Amended and Restated Non-Employee Directors Stock Award Plan. Each restricted stock unit represents a contingent right to receive one ordinary share upon the vesting of the unit. Subject to the Reporting Person's continuous service and certain additional conditions, these units will vest in full on July 29, 2022. Read SEC document |
| May 20, 2021 Filed May 24, 2021 22:19 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | Tax withholdingOrdinary Shares | 11,404 | $17.80 | $202,991.20 |
DisclosureSEC source: 0001179110-21-005852 · edgar.xml · nonDerivative · entry 1 Winningham Rick E · CIK 0001302443 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,324,818 F1 · balance_after: Includes 1,401 shares acquired under the Theravance Biopharma, Inc. 2013 Employee Share Purchase Plan on May 14, 2021. Read SEC document |
| February 20, 2021 Filed Feb 23, 2021 23:17 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | Tax withholdingOrdinary Shares | 110,348 | $18.79 | $2,073,438.92 |
DisclosureSEC source: 0001179110-21-002176 · edgar.xml · nonDerivative · entry 1 Winningham Rick E · CIK 0001302443 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,334,821 Read SEC document |
| February 08, 2021 Filed Feb 10, 2021 22:53 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | GrantOrdinary Shares | 170,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-21-001541 · edgar.xml · nonDerivative · entry 1 Winningham Rick E · CIK 0001302443 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,445,169 Read SEC document |
| November 20, 2020 Filed Nov 24, 2020 23:24 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | Tax withholdingOrdinary Shares | 13,946 | $17.21 | $240,010.66 |
DisclosureSEC source: 0001179110-20-011377 · edgar.xml · nonDerivative · entry 1 Winningham Rick E · CIK 0001302443 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,275,169 Read SEC document |
| August 20, 2020 Filed Aug 24, 2020 22:36 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | Tax withholdingOrdinary Shares | 13,946 | $18.22 | $254,096.12 |
DisclosureSEC source: 0001179110-20-009275 · edgar.xml · nonDerivative · entry 1 Winningham Rick E · CIK 0001302443 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,289,115 Read SEC document |
| August 07, 2020 Filed Aug 10, 2020 20:57 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | SaleOrdinary Shares | 931 | $125.87 | $117,184.88 |
DisclosureSEC source: 0001765581-20-000085 · edgardoc.xml · nonDerivative · entry 2 Winningham Rick E · CIK 0001302443 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,198 F2 · kind: Shares sold to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. Read SEC document |
| August 06, 2020 Filed Aug 10, 2020 20:57 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 6,765 | $0.00 Strike: $127.07 | $0.00 |
DisclosureSEC source: 0001765581-20-000085 · edgardoc.xml · derivative · entry 3 Winningham Rick E · CIK 0001302443 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,765 Underlying: Ordinary Shares · 6,765 shares Expires 2030-08-05 F3 · derivative.exercise_date: These options are granted pursuant to the Issuer's 2007 Amended and Restated Non-Employee Directors Stock Award Plan. Subject to the Reporting Person's continuous service and certain additional conditions, these options will vest in full on July 30, 2021. Read SEC document |
| August 06, 2020 Filed Aug 10, 2020 20:57 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | GrantOrdinary Shares | 2,705 | $0.00 | $0.00 |
DisclosureSEC source: 0001765581-20-000085 · edgardoc.xml · nonDerivative · entry 1 Winningham Rick E · CIK 0001302443 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,129 F1 · kind: These restricted stock units are granted pursuant to the Issuer's 2007 Amended and Restated Non-Employee Directors Stock Award Plan. Each restricted stock unit represents a contingent right to receive one ordinary share upon the vesting of the unit. Subject to the Reporting Person's continuous service and certain additional conditions, these units will vest in full on July 30, 2021. Read SEC document |
| May 20, 2020 Filed May 22, 2020 22:13 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | Tax withholdingOrdinary Shares | 13,946 | $26.67 | $371,939.82 |
DisclosureSEC source: 0001179110-20-006535 · edgar.xml · nonDerivative · entry 1 Winningham Rick E · CIK 0001302443 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,303,061 F1 · balance_after: Includes 1,402 shares acquired under the Theravance Biopharma, Inc. 2013 Employee Share Purchase Plan on May 15, 2020. Read SEC document |
| February 20, 2020 Filed Feb 25, 2020 00:15 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | Tax withholdingOrdinary Shares | 96,850 | $25.90 | $2,508,415.00 |
DisclosureSEC source: 0001179110-20-002156 · edgar.xml · nonDerivative · entry 1 Winningham Rick E · CIK 0001302443 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,315,605 Read SEC document |
| February 03, 2020 Filed Feb 6, 2020 00:06 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | GrantOrdinary Shares | 168,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-20-001210 · edgar.xml · nonDerivative · entry 2 Winningham Rick E · CIK 0001302443 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,412,455 F1 · shares: On March 15, 2016, the reporting person was granted a performance stock award that vests based on the achievement of certain performance conditions over a five-year timeframe from 2016 through December 31, 2020 and continued employment. On February 3, 2020, the performance conditions applicable to 168,000 shares were achieved and such shares will vest on February 20, 2021, subject to the reporting person's continued service. Read SEC document |
| February 03, 2020 Filed Feb 6, 2020 00:06 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | GrantOrdinary Shares | 170,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-20-001210 · edgar.xml · nonDerivative · entry 1 Winningham Rick E · CIK 0001302443 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,244,455 Read SEC document |
| November 20, 2019 Filed Nov 22, 2019 23:26 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | Tax withholdingOrdinary Shares | 8,678 | $17.60 | $152,732.80 |
DisclosureSEC source: 0001179110-19-012023 · edgar.xml · nonDerivative · entry 1 Winningham Rick E · CIK 0001302443 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,074,455 Read SEC document |
| August 20, 2019 Filed Aug 22, 2019 22:07 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | Tax withholdingOrdinary Shares | 8,678 | $21.51 | $186,663.78 |
DisclosureSEC source: 0001179110-19-009798 · edgar.xml · nonDerivative · entry 1 Winningham Rick E · CIK 0001302443 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,083,133 Read SEC document |
| August 09, 2019 Filed Aug 12, 2019 21:48 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | SaleOrdinary Shares | 726 | $135.65 | $98,482.19 |
DisclosureSEC source: 0001765581-19-000080 · edgardoc.xml · nonDerivative · entry 2 Winningham Rick E · CIK 0001302443 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,424 F2 · kind: Shares sold to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. F3 · price: Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $135.65 to $135.7285. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected. Read SEC document |
| August 08, 2019 Filed Aug 12, 2019 21:48 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 4,805 | $0.00 Strike: $137.12 | $0.00 |
DisclosureSEC source: 0001765581-19-000080 · edgardoc.xml · derivative · entry 3 Winningham Rick E · CIK 0001302443 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,805 Underlying: Ordinary Shares · 4,805 shares Expires 2029-08-07 F4 · kind: These options are granted pursuant to the Issuer's 2007 Non-Employee Directors Stock Award Plan. Subject to the Reporting Person's continuous service and certain additional conditions, these options will vest in 12 equal monthly installments beginning on September 1, 2019. F4 · derivative.exercise_date: These options are granted pursuant to the Issuer's 2007 Non-Employee Directors Stock Award Plan. Subject to the Reporting Person's continuous service and certain additional conditions, these options will vest in 12 equal monthly installments beginning on September 1, 2019. Read SEC document |
| August 08, 2019 Filed Aug 12, 2019 21:48 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | GrantOrdinary Shares | 1,920 | $0.00 | $0.00 |
DisclosureSEC source: 0001765581-19-000080 · edgardoc.xml · nonDerivative · entry 1 Winningham Rick E · CIK 0001302443 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,150 F1 · kind: These restricted stock units are granted pursuant to the Issuer's 2007 Non-Employee Directors Stock Award Plan. Each restricted stock unit represents a contingent right to receive one ordinary share upon the vesting of the unit. Subject to the Reporting Person's continuous service and certain additional conditions, these units will vest in full on August 1, 2020. Read SEC document |
| May 20, 2019 Filed May 22, 2019 22:17 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | Tax withholdingOrdinary Shares | 8,678 | $19.84 | $172,171.52 |
DisclosureSEC source: 0001179110-19-006538 · edgar.xml · nonDerivative · entry 1 Winningham Rick E · CIK 0001302443 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,091,811 F1 · balance_after: Includes 1,027 shares acquired under the Theravance Biopharma, Inc. 2013 Employee Share Purchase Plan on May 15, 2019. Read SEC document |
| February 20, 2019 Filed Feb 22, 2019 23:25 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | Tax withholdingOrdinary Shares | 13,477 | $27.00 | $363,879.00 |
DisclosureSEC source: 0001179110-19-002433 · edgar.xml · nonDerivative · entry 1 Winningham Rick E · CIK 0001302443 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,099,462 Read SEC document |
| February 05, 2019 Filed Feb 7, 2019 22:50 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | GrantOrdinary Shares | 147,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-19-001572 · edgar.xml · nonDerivative · entry 2 Winningham Rick E · CIK 0001302443 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,112,939 F1 · shares: On March 15, 2016, the reporting person was granted a performance stock award that vests based on the achievement of certain performance conditions over a five-year timeframe from 2016 through December 31, 2020 and continued employment. On February 5, 2019, the performance conditions applicable to 147,000 shares were achieved and such shares will vest on February 20, 2020, subject to the reporting person's continued service. Read SEC document |
| February 05, 2019 Filed Feb 7, 2019 22:50 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | GrantOrdinary Shares | 170,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-19-001572 · edgar.xml · nonDerivative · entry 1 Winningham Rick E · CIK 0001302443 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 965,939 Read SEC document |
| November 20, 2018 Filed Nov 21, 2018 22:47 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | Tax withholdingOrdinary Shares | 15,557 | $24.79 | $385,658.03 |
DisclosureSEC source: 0001179110-18-013111 · edgar.xml · nonDerivative · entry 1 Winningham Rick E · CIK 0001302443 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 795,939 Read SEC document |
| August 24, 2018 Filed Feb 5, 2019 22:22 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | GiftOrdinary Shares | 1,720 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-19-002650 · doc5.xml · nonDerivative · entry 1 Winningham Rick E · CIK 0001302443 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,230 F1 · kind: Represents ordinary shares that the Reporting Person donated as a gift to the Fidelity Investment Charitable Gift Fund, a donor advised fund. Read SEC document |
| August 20, 2018 Filed Aug 22, 2018 23:35 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | Tax withholdingOrdinary Shares | 15,557 | $26.95 | $419,261.15 |
DisclosureSEC source: 0001179110-18-010823 · edgar.xml · nonDerivative · entry 1 Winningham Rick E · CIK 0001302443 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 904,063 Read SEC document |
| August 10, 2018 Filed Aug 13, 2018 22:05 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | SaleOrdinary Shares | 660 | $176.61 | $116,563.13 |
DisclosureSEC source: 0001232524-18-000136 · edgardoc.xml · nonDerivative · entry 7 Winningham Rick E · CIK 0001302443 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,950 F3 · kind: Shares sold to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $176.61 to $177.1555, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| August 09, 2018 Filed Aug 13, 2018 22:05 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 3,735 | $0.00 Strike: $177.73 | $0.00 |
DisclosureSEC source: 0001232524-18-000136 · edgardoc.xml · derivative · entry 10 Winningham Rick E · CIK 0001302443 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,735 Underlying: Ordinary Shares · 3,735 shares Expires 2028-08-08 F7 · derivative.exercise_date: These options are granted pursuant to the Issuer's 2007 Non-Employee Directors Stock Award Plan. Subject to the Reporting Person's continuous service and certain additional conditions, these options will vest in 12 equal monthly installments beginning on September 1, 2018. Read SEC document |
| August 09, 2018 Filed Aug 13, 2018 22:05 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 4,500 | $0.00 Strike: $81.76 | $0.00 |
DisclosureSEC source: 0001232524-18-000136 · edgardoc.xml · derivative · entry 9 Winningham Rick E · CIK 0001302443 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 4,500 shares Expires 2023-08-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: This non-qualified stock option was granted on August 8, 2013 and vested over a period of one year from September 1, 2013. The options were fully vested as of August 1, 2014. Read SEC document |
| August 09, 2018 Filed Aug 13, 2018 22:05 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 4,500 | $0.00 Strike: $46.83 | $0.00 |
DisclosureSEC source: 0001232524-18-000136 · edgardoc.xml · derivative · entry 8 Winningham Rick E · CIK 0001302443 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 4,500 shares Expires 2022-08-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: This non-qualified stock option was granted on August 9, 2012 and vested over a period of one year from the grant date. The options were fully vested as of August 9, 2013. Read SEC document |
| August 09, 2018 Filed Aug 13, 2018 22:05 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | SaleOrdinary Shares | 3,437 | $176.03 | $605,015.45 |
DisclosureSEC source: 0001232524-18-000136 · edgardoc.xml · nonDerivative · entry 6 Winningham Rick E · CIK 0001302443 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,610 Read SEC document |
| August 09, 2018 Filed Aug 13, 2018 22:05 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | SaleOrdinary Shares | 3,542 | $176.31 | $624,481.17 |
DisclosureSEC source: 0001232524-18-000136 · edgardoc.xml · nonDerivative · entry 5 Winningham Rick E · CIK 0001302443 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,047 Read SEC document |
| August 09, 2018 Filed Aug 13, 2018 22:05 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | GrantOrdinary Shares | 1,495 | $0.00 | $0.00 |
DisclosureSEC source: 0001232524-18-000136 · edgardoc.xml · nonDerivative · entry 4 Winningham Rick E · CIK 0001302443 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,589 F2 · kind: These restricted stock units are granted pursuant to the Issuer's 2007 Non-Employee Directors Stock Award Plan. Each restricted stock unit represents a contingent right to receive one ordinary share upon the vesting of the unit. Subject to the Reporting Person's continuous service and certain additional conditions, these units will vest in full on August 2, 2019. Read SEC document |
| August 09, 2018 Filed Aug 13, 2018 22:05 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | SaleOrdinary Shares | 9,000 | $176.15 | $1,585,341.00 |
DisclosureSEC source: 0001232524-18-000136 · edgardoc.xml · nonDerivative · entry 3 Winningham Rick E · CIK 0001302443 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,094 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $176.14 to $176.22, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| August 09, 2018 Filed Aug 13, 2018 22:05 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | Exercise / conversionOrdinary Shares | 4,500 | $46.83 | $210,735.00 |
DisclosureSEC source: 0001232524-18-000136 · edgardoc.xml · nonDerivative · entry 2 Winningham Rick E · CIK 0001302443 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,094 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 09, 2018 Filed Aug 13, 2018 22:05 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | Exercise / conversionOrdinary Shares | 4,500 | $81.76 | $367,920.00 |
DisclosureSEC source: 0001232524-18-000136 · edgardoc.xml · nonDerivative · entry 1 Winningham Rick E · CIK 0001302443 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,594 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 22, 2018 Filed Jun 25, 2018 18:07 UTC | OncoMed Pharmaceuticals Inc OMED · Entity 158190 | GrantStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $2.55 | $0.00 |
DisclosureSEC source: 0001140361-18-029837 · doc1.xml · derivative · entry 1 Winningham Rick E · CIK 0001302443 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2028-06-22 F1 · derivative.exercise_date: The option vests as to 100% of the shares subject thereto upon the earlier of one year following the grant date or the date of the subsequent year's annual meeting of stockholders, subject to the Reporting Person's continued service to the Issuer through such vesting date. Read SEC document |
| May 20, 2018 Filed May 22, 2018 23:03 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | Tax withholdingOrdinary Shares | 67,617 | $24.31 | $1,643,769.27 |
DisclosureSEC source: 0001179110-18-007376 · edgar.xml · nonDerivative · entry 1 Winningham Rick E · CIK 0001302443 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 919,620 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.